Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2017-05-02 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It details a 'Correction of a publication' regarding a 'Conditional capital increase' and states the 'New total number of voting rights: 29.318.110'. This content directly relates to changes in the company's capital structure and voting rights, which falls under the scope of capital/financing updates or specific regulatory disclosures about share structure. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it concerns a capital measure (conditional capital increase) affecting the total number of shares/rights. While it is a regulatory announcement, CAP is more specific than the general RNS fallback.
2017-05-02 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a of the WpHG (German Securities Trading Act). It details a 'Type of capital measure' which is a 'Conditional capital increase' and reports the 'New total number of voting rights' as 29,318,110 as of April 28, 2017. This type of announcement, dealing with changes in the total number of shares/voting rights, fits best under Capital/Financing Update (CAP) or potentially Share Issue/Capital Change (SHA). Since it is a formal announcement regarding the structure of capital (conditional increase and total rights), SHA is the most precise fit, as it covers capital structure changes, which includes changes in the total number of shares outstanding.
2017-04-28 English
MorphoSys to Host Q1 2017 Conference Call on May 3, 2017 (news with additional features)
Report Publication Announcement Classification · 99% confidence The document is a news release dated April 24, 2017, announcing that MorphoSys AG will publish its Q1 2017 results on May 3, 2017, and will host a public conference call and webcast to present these results. The key elements are the announcement of an upcoming earnings release and the scheduling of a conference call to discuss the 'first quarter interim statement 2017'. Since the document itself is an announcement about the upcoming release of financial results and the associated call, it functions as a notification. However, the primary focus is the scheduling of the conference call itself, which aligns best with the 'Call Transcript' (CT) definition if the transcript were present, or the 'Earnings Release' (ER) if it contained the results. Since it is purely an announcement *about* the call and the results publication, and not the results themselves, it is a precursor announcement. Given the strong emphasis on hosting the conference call ('MorphoSys to Host Q1 2017 Conference Call'), the most fitting category among the options that relate to earnings events is 'Call Transcript' (CT) if we interpret this as the announcement leading up to the call, or 'Earnings Release' (ER) if we consider it the initial notification of the period's performance announcement. Because it explicitly mentions hosting the call to present the 'interim statement 2017', it is closely tied to the earnings cycle. If the document contained the actual Q1 results, it would be 'IR' (Interim Report). Since it is the announcement of the call to discuss the interim results, it is most closely related to the event itself. However, looking at the definitions, 'CT' is for the full transcript, and 'ER' is for the initial announcement of results (key highlights). This document announces *when* the results will be published and *when* the call will happen. It is a pre-announcement. In many databases, such an announcement is classified as a Regulatory Filing (RNS) or sometimes grouped with the Earnings Release (ER). Given the content is about scheduling the discussion of the Q1 results, and it is a formal DGAP news item, it is a regulatory announcement. Since it is not the actual earnings release (ER) or the interim report (IR), and it is not the transcript (CT), the most appropriate general category for a scheduled event announcement that doesn't fit the specific report types is RNS, or potentially ER as it signals the upcoming earnings event. Given the strong focus on the conference call, and the fact that it is a news release about an upcoming event, I will classify it as a Regulatory Filing (RNS) as it is a general announcement disseminated via DGAP, or ER as it is directly tied to the earnings cycle. Since it is a formal announcement about an upcoming earnings event, ER is a strong candidate, but RNS is the fallback for general regulatory news. I will lean towards ER as the subject matter is earnings-related, even if it's just the scheduling. Re-evaluating: The document is a news release announcing the date/time of the Q1 results publication and the subsequent conference call. This is a standard pre-earnings announcement. It is not the ER (which contains the highlights) nor the CT (which is the transcript). It is a regulatory announcement about future events. RNS is the best fit for a general regulatory announcement that doesn't fit the specific report types (10-K, IR, ER, etc.). I will use RNS as the most accurate fallback for this type of scheduling announcement.
2017-04-24 English
MorphoSys to Present at Upcoming Conferences (news with additional features)
Report Publication Announcement Classification · 99% confidence The document is a news release from MorphoSys AG announcing its participation in several upcoming industry conferences (Kempen Life Sciences, UBS Global Healthcare, Berenberg European Conference) where company executives will present. It also mentions the date of the upcoming Annual General Meeting (AGM) and provides a link for webcast information. Since the primary content is an announcement about future events and presentations, and it is not the presentation itself, the most fitting category is Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it specifically announces where and when management will present, and also mentions the AGM date, it functions as a general corporate update/announcement. However, since it is a news release announcing future events rather than a specific report (like 10-K, ER, or IP), and it is not a proxy solicitation (PSI) or a formal AGM material (AGM-R), the best fit among the provided options for a general corporate announcement about future activities is often RNS, or potentially RPA if it were announcing the release of a specific report. Since it announces participation in conferences and mentions the AGM date, it is a general corporate communication. I will classify it as RNS (Regulatory Filings) as it is a general news release disseminated via DGAP that doesn't fit the more specific categories like ER, IP, or AGM-R (which would be the materials *from* the AGM). The document length is moderate (5270 chars), but the content is purely informational about future events, not the event materials themselves.
2017-04-11 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction (purchase of shares) by an individual identified as a 'Member of the managing body' (Jens Holstein). This content directly matches the definition for Director's Dealing reports.
2017-04-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details the name of the person (Jens Holstein), their position ('Member of the managing body'), the nature of the transaction ('Disposal'), and extensive tables listing prices and volumes of share transactions. This content directly matches the definition for Director's Dealing (Insider Trades).
2017-04-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.